Renal patients' views on generic prescribing and substitution: Example from the united arab emirates;Points de vue des patients atteints d'une maladie rénale sur la prescription des génériques et leur utilisation en substitution: Exemple des émirats arabes unis

Eastern Mediterranean Health Journal

Volumn 19, Issue 4, 2013, Pages 373-381

  Al Ameri, M N ^a,b   Mohamed, W ^b   Makramalla, E ^b   Shalhoub, B ^c   Tucker, A ^a   Johnston, A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Global Medical Solutions   (United Arab Emirates)

^c Health Authority Abu Dhabi   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GENERIC DRUG; CYCLOSPORIN A;

ADULT; AGED; ARTICLE; AWARENESS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG INFORMATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIPLE CHOICE TEST; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PRESCRIPTION; TREATMENT REFUSAL; UNITED ARAB EMIRATES; EDUCATION; HEALTH CARE PERSONNEL; HEALTH SURVEY; KNOWLEDGE; MULTICENTER STUDY; PATIENT; QUESTIONNAIRE; RENAL PATIENT; TRAINING;

EID: 84878091501     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2013.19.4.373     Document Type: Article

References (34)

1. Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. III: Regulating industry. BMJ (Clinical Research Ed.), 1996 313(7048):33-35
2. The medicinal consumption in the UAE has reached four billion Dirhams in 2010. Alittihad (online newspaper), March 5th, 2011 [in Arabic].
3. Andersson K. et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiology and Drug Safety, 2005, 14(5):341-348
4. Tilson L, Bennett K, Barry M. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland. European Journal of Health Economics, 2005, 6(3):267-273
5. Abu Dhabi moves towards generic prescribing. Datamonitor, 20 April 2009 (http://www.datamonitor.com/store/News/abu_dhabi_moves_towards_generic_prescribing?productid=0F02EAF3-3EAB-4C7C-87F6-8530E731DA65, accessed 14 Jan 2013).
6. Himmel W et al. What do primary care patients think about generic drugs? International Journal of Clinical Pharmacology and Therapeutics, 2005, 43(10):472-479
7. Garattini S, Bertelé V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet, 2007, 370(9602):1875-1877
8. Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? British Journal of Clinical Pharmacology, 2010, 70(3):335-341
9. Chow S-C. Individual bioequivalence-a review of the FDA Draft Guidance. Drug Information Journal, 1999, 33:435-444
10. AlAmeri M, Epstein M, Johnston A. Generic and therapeutic substitutions: are they always ethical in their own terms? Pharmacy World & Science, 2010, 32(6):691-695
11. Christians U, Klawitter J, Clavijo CF. Bioequivalence testing of immunosuppressants: concepts and misconceptions. Kidney International, 2010, 77(115 Suppl.):S1-S7
12. Generic substitution terminated for oral medicines containing cyclosporine or tacrolimus. Sundhedsstyrelsen, July 13th 2011, Danish Health and Medicines Authority (http://laegemiddelstyrelsen.dk/en/topics/authorisation-and-supervision/licensing-of-medicines/news/generic-substitution-terminated-for-oral--tacrolimus, accessed 21 January 2013).
13. Prescriptions dispensed in the community: statistics for 1996 to 2006. London, NHS National Statistics, The NHS Information Centre (Health Care) (Bulletin: IC 2007 11.11).
14. Dombrowski C. UK drug pricing scheme to allow generic substitution, promote innovation. EuroPharma Today, November 24, 2008 (http://www.europharmatoday.com/2008/11/ukdrug-pricing-scheme-to-allow-generic-substitution-promoteinnovation.html, accessed 21 january 2013).
15. Helderman JH et al. Healthcare costs in renal transplant recipients using branded versus generic ciclosporin. Applied Health Economics and Health Policy, 2010, 8(1):61-68.
16. Kingma I et al. Economic analysis of Neoral in de novo renal transplant patients in Canada. Clinical Transplantation, 1997, 11(1):42-48.
17. Cox DC et al. Guidelines for dissolution testing. Pharmaceutical Technology, 1978, 2(4):40-53.
18. Kamerow D. The pros and cons of generic drugs. BMJ, 2011, 343:d4584
19. Bioequivalence and labelling of medicinal products with regard to generic substitution. Sundhedsstyrelsen, July 13th 2011, Danish Health and Medicines Authority (http://www.dkma.dk/en/topics/authorisation-and-supervision/licensing-of-medicines/marketing-authorisation/applicationfor-marketing-authorisation/bioequivalence-and-labellingof-medicine--bstitution, accessed 21 january 2013).
20. Frank RG. The ongoing regulation of generic drugs. New England Journal of Medicine, 2007, 357(20):1993-1996.
21. Kozlowski S et al. Developing the nation's biosimilars program. New England Journal of Medicine, 2011, 365(5):385-388.
22. Al Ameri MN et al. A survey to determine the views of renal transplant patients on generic substitution in the UK. Transplant International, 2011, 24(8):770-779.
23. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clinical Therapeutics, 2003, 25(11):2875-2890.
24. Weinman J. Providing written information for patients: psychological considerations. Journal of the Royal Society of Medicine, 1990, 83:303-305.
25. AbduelkaremAR, SharifSI. Current levels of interaction between the physician and pharmacist: a comparative study in Libya and UAE. Jordan Journal of Pharmaceutical Sciences, 2008, 1(2):142-151.
26. UAE Guidelines of Bioequivalence Testing for Generic Pharmaceutical Products 2001. Dubai, United Arab Emirates, Ministry of Health, 2011 (http://www.cpd-pharma.ae/index. php?option=com_phocadownload&view=category&id=2&Itemid=78&limitstart=20, accessed 21 January 2013).
27. Simoens S. Generic and therapeutic substitution: ethics meets health economics. International Journal of Clinical Pharmacology, Therapy and Toxicology, 2011, 33(3):469-470.
28. Masri M. The generics in transplantation and the rules on their use. Experimental and Clinical Transplantation, 2003, 1(1):65-68.
29. Berg MJ et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology, 2008, 71(7):525-530.
30. Richton-Hewett S, Foster E, Apstein CS. Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital. Archives of Internal Medicine, 1988, 148(4):806-808.
31. Kovarik JM et al. Differentiation of innovator versus generic cyclosporine via a drug interaction on sirolimus. European Journal of Clinical Pharmacology, 2006, 62(5):361-366.
32. Qazi YA et al. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clinical Transplantation, 2006, 20(3):313-317.
33. Taber DJ et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation, 2005, 80(11):1633-1635
34. Approved drug products with therapeutic equivalence evaluations (Orange book). Silver Springs, Maryland, US Food and Drug Administration, 2009.